Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition

cafead

Administrator
Staff member
  • cafead   Sep 11, 2023 at 12:32: PM
via Novartis is discontinuing the development of GT005, a mid-stage investigational gene therapy being developed for geographic atrophy secondary to dry age-related macular degeneration.

article source
 

<